GlassScriptPhysician profile
Richa Bhattarai
NPI 1407298458
$587.68
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $95.94.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.61 | 2019 | |
| Novo Nordisk INC | $69.65 | 2019-2020 | |
| Abbvie INC. | $62.56 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $61.11 | 2019 | |
| Shire North American Group INC | $47.82 | 2019 | |
| Lilly USA, LLC | $42.87 | 2019 | |
| Medtronic Minimed, INC. | $37.60 | 2019 | |
| Amgen INC. | $32.16 | 2020 | |
| Merck Sharp & Dohme LLC | $28.71 | 2019-2020 | |
| Lifescan, INC. | $22.63 | 2019 | |
| Insulet Corporation | $20.36 | 2019 | |
| Abbott Laboratories | $16.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.06 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.71 | 2019 | |
| Mannkind Corporation | $11.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richa Bhattarai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.